Replies to post #217438 on Biotech Values

[DewDiligence]

ADXS—FDA clinical hold on phase-2 trial of AXAL+AZN’s Imfinzi in cervical cancer; other ADXS trials—including the AIM2CERV phase-3 trial of AXAL monotherapy in adjuvant cervical cancer—are unaffected:

http://ir.advaxis.com/press-release/advaxis-reports-fiscal-2018-first-quarter-financial-results-and-announces-clinical

The reason for the clinical hold is one unexplained death in the Imfinza trial.

The above PR also includes ADXS' FY1Q18 (1/31/18) financials.

[DewDiligence]

ADXS files $250M shelf registration, superseding the shelf registration filed in Feb 2017:

https://www.sec.gov/Archives/edgar/data/1100397/000149315218012519/forms-3.htm

https://www.sec.gov/Archives/edgar/data/1100397/000149315217001337/forms-3.htm